Recursion Pharmaceuticals
RXRX
146 hedge funds and large institutions have $1.21B invested in Recursion Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 63 increasing their positions, 29 reducing their positions, and 11 closing their positions.
142% more call options, than puts
Call options by funds: $1.1M | Put options by funds: $455K
118% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 11
117% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 29
40% more capital invested
Capital invested by funds: $861M → $1.21B (+$349M)
10% more funds holding
Funds holding: 133 → 146 (+13)
3.87% more ownership
Funds ownership: 64.98% → 68.85% (+3.9%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$24.6M |
| 2 |
BlackRock
New York
|
+$15.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.1M |
| 5 |
DFO
Duquesne Family Office
New York
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMS
Obvious Management Services
San Francisco,
California
|
-$20.2M |
| 2 |
TSV
Two Sigma Ventures
New York
|
-$9.15M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$3.81M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$3.68M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$2.87M |
RXRX Hedge Fund Activity: Q3 2022 in Review
146 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2022, worth a combined $1.21B — up 40% from $861M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RXRX positions and 11 closed out — a net gain of 13 holders — while 63 added to existing stakes and 29 trimmed.
The largest buyer was State Street, adding an estimated $24.6M. The largest seller was Obvious Management Services, cutting an estimated $20.2M.
- 146 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2022, up from 133 in Q2 2022.
- Funds reported $1.21B of Recursion Pharmaceuticals stock for Q3 2022, up 40% quarter-over-quarter.
- 24 funds opened new Recursion Pharmaceuticals positions in Q3 2022 and 11 closed out, a net change of +13 holders.
- The largest Recursion Pharmaceuticals buyer in Q3 2022 was State Street, an estimated $24.6M added.
- The largest Recursion Pharmaceuticals seller in Q3 2022 was Obvious Management Services, an estimated $20.2M sold.
Based on aggregated 13F filings for Q3 2022.